Navigation Links
183 New Medicines in Development for Diabetes
Date:12/11/2009

WASHINGTON, Dec. 11 /PRNewswire-USNewswire/ -- Nabe News in Brooklyn, New York recently reported that 183 new medicines are in development to fight diabetes. The report details a record number of drugs for this chronic disease currently in human clinical trials and awaiting approval by the U.S. Food and Drug Administration. The report was released by America's pharmaceutical research and biotechnology companies (PhRMA).

Diabetics do not produce or properly use insulin, a hormone needed to convert sugar, starches and other food into energy. This chronic disease affects 24.7 percent of Brooklyn's adults, or 449,900 people, according to the Centers for Disease Control and Prevention.

"This killer thrives in communities like ours, where poverty and fast food are prevalent," said Dr. Richard Becker, president and CEO of the Brooklyn Hospital Center.

Rep. Edolphus Towns, who suffers from diabetes, attended the event at the Brooklyn Hospital Center as well.

"Developing new drugs to treat diabetes here in New York City will help address one of the major diseases affecting our community," the lawmaker said. Of New York's five boroughs, Brooklyn has the second highest rate of diabetes.

According to PhRMA, one of the drugs in development significantly improves long-term blood sugar control and targets the dysfunction of pancreas cells, a dysfunction that causes high sugar level in type 2 diabetes, the most common form of the disease. Another medicine in development stimulates the release of insulin only when glucose levels become too high and by suppressing appetite in patients with type 2 diabetes.

"The medicines now in the research pipelines are contributing significantly to the incredible progress made by America's pharmaceutical research and biotechnology companies in developing new treatments for diabetes and related conditions," said Ed Belkin, PhRMA vice president for communications and public affairs.

To read the full story, go to the Nabe News web site.

SOURCE Pharmaceutical Research and Manufacturers of America


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. 92 Medicines and Vaccines now in Development for HIV/AIDS
2. New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline
3. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
4. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
5. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
6. Report on 750 New Medicines in Development for Cancer Released in Baton Rouge
7. European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina
8. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
9. More Than 300 New Medicines Being Developed for Mental Illnesses
10. Report on 300 New Medicines in Development for Heart Disease and Stroke Released in Indianapolis
11. New Report Shows Record Number of Medicines in Development to Treat Leading Causes of Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , 22 de marzo de 2017 /PRNewswire/ ... global líder de soluciones de productos y servicios ... hoy que ha adquirido EPL Archives, Inc., una ... los clientes en todo el ciclo de vida ... ofreciendo una muestra de archivo, almacenamiento de documentos ...
(Date:3/22/2017)... DUBLIN , Mar. 22, 2017 Research ... Care Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 10.9% over the next ... This industry report analyzes the market estimates and forecasts for all ...
(Date:3/22/2017)... March 22, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... health and big data solutions, today reported financial ... month period ended December 31, 2016. ... $2.8 million, increased 241% compared to the full ... growth throughout the entire year  ...
Breaking Medicine Technology:
(Date:3/22/2017)... CA (PRWEB) , ... March 22, 2017 , ... ... the California Bay Area providing insurance assistance, financial planning, and related services to ... Endangered Species International to promote awareness of threatened species and wild lands. , ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... Milpitas with a robust, ongoing community enrichment program, has announced their latest charity ... which has provided for the critical needs of homeless families with children for ...
(Date:3/22/2017)... ... March 22, 2017 , ... The American ... prior authorization (PA) form for prescribers to improve patients’ access to the revolutionary ... tools published as part of the article entitled “PCSK9 Inhibitor Access Barriers: ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... Old School ... boxing champ Ashley Theophane as a new Brand Ambassador. Theophane, who trained with Floyd ... welterweight title in 2011. He has racked up an impressive number of wins in ...
(Date:3/22/2017)... ... 2017 , ... Soriant recognizes that identifying savings opportunities can ... facilities across the country are always forced to focus on costs and budgets. ... country, an efficient and quick way to estimate savings potential within specific support ...
Breaking Medicine News(10 mins):